DDIT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: Notably, in a phase III study of untreated PTCL patients (NCT01796002), the addition of romidepsin to CHOP (Ro-CHOP) did not improve PFS (12.0 months vs. 10.2 months, Ro-CHOP vs. CHOP), ORR (63% vs. 60%), or OS (51.8 months vs. 42.9 months) but resulted in more AEs (70).